COMMUNIQUÉS West-GlobeNewswire

AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market

19/12/2024 - 23:05

New collagen-based dermal matrix designed for tissue generation, complementary to RECELL and PermeaDerm Cohealyx expected to triple AVITA Medical’s addressable market in burns VALENCIA, Calif., Dec. 19, 2024 (GLOBE [...]

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

19/12/2024 - 23:25

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- [...]

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

19/12/2024 - 23:33

Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure [...]

U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

19/12/2024 - 20:58

Company announcement – No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome The FDA concluded that Zealand [...]

CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

19/12/2024 - 21:45

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS 19 DECEMBER 2024 at 22.45 EET CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed [...]

OraSure Technologies Acquires Sherlock Biosciences

19/12/2024 - 22:02

BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition [...]

Aptose Announces Positive Decision by Nasdaq Hearings Panel

19/12/2024 - 22:05

SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated [...]

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options

19/12/2024 - 22:05

Budget impact analysis published in the Expert Review of Ophthalmology journal MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare [...]

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19/12/2024 - 22:05

SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

19/12/2024 - 22:05

Company on track to initiate the Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and in other age groups in 2025 NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. ( [...]

Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025

19/12/2024 - 22:05

Webcast Scheduled for Thursday, January 2 at 4:30 p.m. Eastern CHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and [...]

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

19/12/2024 - 22:08

- The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell [...]

Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

19/12/2024 - 22:10

AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and [...]

Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

19/12/2024 - 22:15

Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: [...]

Epitopea and Genevant Sciences Announce Collaboration Agreement

19/12/2024 - 22:30

CAMBRIDGE, United Kingdom and MONTREAL and VANCOUVER, British Columbia and BASEL, Switzerland, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the- [...]

Epitopea et Genevant Sciences annoncent une entente de collaboration

19/12/2024 - 22:35

CAMBRIDGE, Royaume-Uni et MONTRÉAL et VANCOUVER, Colombie-Britannique et BÂLE, Suisse, 19 déc. 2024 (GLOBE NEWSWIRE) -- Epitopea, une société transatlantique d’immunothérapies anticancéreuses qui met au point des [...]

ONWARD Medical Receives FDA De Novo Classification and US Market Authorization for World’s First Non-Invasive Spinal Cord Stimulation System for People with Chronic Spinal Cord Injury

19/12/2024 - 17:58

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) ARC-EX System is the first and only FDA approved technology shown to improve hand [...]

Communiqué de presse - Jean-Paul Kress rejoint le Conseil d’administration de Sanofi

19/12/2024 - 18:00

Jean-Paul Kress rejoint le Conseil d’administration de Sanofi Paris, le 19 décembre 2024 . Le Conseil d’administration de Sanofi est heureux d’accueillir Jean-Paul Kress en qualité d’administrateur indépendant à compter [...]

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

19/12/2024 - 18:00

Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024 . Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025, replacing Gilles Schnepp [...]